117 related articles for article (PubMed ID: 17608842)
1. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease.
Inoue S; Nakase H; Matsuura M; Ueno S; Uza N; Kitamura H; Mikami S; Tamaki H; Kasahara K; Chiba T
J Gastroenterol Hepatol; 2007 Jul; 22(7):984-8. PubMed ID: 17608842
[TBL] [Abstract][Full Text] [Related]
2. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
Selby W; Pavli P; Crotty B; Florin T; Radford-Smith G; Gibson P; Mitchell B; Connell W; Read R; Merrett M; Ee H; Hetzel D;
Gastroenterology; 2007 Jun; 132(7):2313-9. PubMed ID: 17570206
[TBL] [Abstract][Full Text] [Related]
3. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
Korzenik JR; Dieckgraefe BK
Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989
[TBL] [Abstract][Full Text] [Related]
4. Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
[TBL] [Abstract][Full Text] [Related]
5. Open label trial of oral clarithromycin in active Crohn's disease.
Leiper K; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 2000 Jun; 14(6):801-6. PubMed ID: 10848665
[TBL] [Abstract][Full Text] [Related]
6. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone.
Bhatia JK; Korelitz BI; Panagopoulos G; Lobel E; Mirsky F; Sultan K; DiSanti W; Chun A; Keenan G; Mamun K
J Clin Gastroenterol; 2007 Aug; 41(7):677-81. PubMed ID: 17667052
[TBL] [Abstract][Full Text] [Related]
7. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial.
D'Haens G; Swijsen C; Noman M; Lemmens L; Ceuppens J; Agbahiwe H; Geboes K; Rutgeerts P
Am J Gastroenterol; 2001 Sep; 96(9):2564-8. PubMed ID: 11569676
[TBL] [Abstract][Full Text] [Related]
8. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
9. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
Chrissafidou A; Malek M; Musch E
Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
[TBL] [Abstract][Full Text] [Related]
10. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
12. Oral butyrate for mildly to moderately active Crohn's disease.
Di Sabatino A; Morera R; Ciccocioppo R; Cazzola P; Gotti S; Tinozzi FP; Tinozzi S; Corazza GR
Aliment Pharmacol Ther; 2005 Nov; 22(9):789-94. PubMed ID: 16225487
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn's disease patients in China.
Zheng JJ; Chu XQ; Shi XH; Zhou CL; Seng BW
J Dig Dis; 2008 May; 9(2):84-8. PubMed ID: 18419641
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.
Vilien M; Dahlerup JF; Munck LK; Nørregaard P; Grønbaek K; Fallingborg J
Aliment Pharmacol Ther; 2004 Jun; 19(11):1147-52. PubMed ID: 15153167
[TBL] [Abstract][Full Text] [Related]
15. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin.
Prantera C; Berto E; Scribano ML; Falasco G
Ital J Gastroenterol Hepatol; 1998 Dec; 30(6):602-6. PubMed ID: 10076781
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of Crohn's disease following corticosteroid-induced remission.
Papi C; Festa V; Leandro G; Moretti A; Tanga M; Koch M; Capurso L
Am J Gastroenterol; 2007 Apr; 102(4):814-9. PubMed ID: 17222316
[TBL] [Abstract][Full Text] [Related]
17. [Azathioprine for prevention of postoperative recurrence in Crohn's disease].
Abdelli MN; Ben Abdallah H; Houissa F; Bouali MR; Khediri MF
Tunis Med; 2007 Jul; 85(7):569-72. PubMed ID: 18064988
[TBL] [Abstract][Full Text] [Related]
18. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars.
Borody TJ; Bilkey S; Wettstein AR; Leis S; Pang G; Tye S
Dig Liver Dis; 2007 May; 39(5):438-44. PubMed ID: 17369114
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study.
Astegiano M; Pagano N; Sapone N; Simondi D; Bertolusso L; Bresso F; Demarchi B; Pellicano R; Bonardi R; Marconi S; Rizzetto M
Biomed Pharmacother; 2007 Jul; 61(6):370-6. PubMed ID: 17399941
[TBL] [Abstract][Full Text] [Related]
20. [Clinical features of Crohn's disease: relationship of disease type and severity to clinical findings at the time of diagnosis in 166 cases].
Tominaga M
Fukuoka Igaku Zasshi; 1992 Jan; 83(1):6-20. PubMed ID: 1547990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
